• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制 Polo 样激酶 1 诱导细胞周期停滞并增强脑胶质瘤细胞对电离辐射的敏感性。

Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.

机构信息

Department of Genetics, University of São Paulo, Brazil.

出版信息

Cancer Biother Radiopharm. 2013 Sep;28(7):516-22. doi: 10.1089/cbr.2012.1415. Epub 2013 May 28.

DOI:10.1089/cbr.2012.1415
PMID:23713868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3741430/
Abstract

Despite efforts to improve surgical, radiologic, and chemotherapeutic strategies, the outcome of patients with glioblastoma (GBM) is still poor. Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays key roles in cell cycle control and has been associated with tumor growth and prognosis. Here, we aimed at testing the radiosensitizing effects of the PLK1 inhibitor BI 2536 on eight GBM cell lines. For cell cycle analysis, T98G, U251, U343 MG-a, LN319, SF188, U138 MG, and U87 MG cell lines were treated with 10, 50, or 100 nM of BI 2536 for 24 hours. In addition, cell cultures exposed to BI 2536 50 nM for 24 hours were irradiated with γ-rays from (60)Cobalt source at final doses of 2, 4, and 6 Gy. Combinatorial effects were evaluated through proliferation and clonogenic capacity assays. Treatment with BI 2536 caused mitotic arrest after 24 hours, and increased apoptosis in GBM cells. Moreover, our results demonstrate that pretreatment with this drug sensitized six out of seven GBM cell lines to different doses of γ-irradiation as shown by decreased growth and abrogation of colony-formation capacity. Our data suggest that PLK1 blockage has a radiosensitizing effect on GBM, which could improve treatment strategies for this devastating tumor.

摘要

尽管在外科手术、放射治疗和化学疗法方面付出了努力,胶质母细胞瘤(GBM)患者的预后仍然较差。丝氨酸/苏氨酸激酶 Polo 样激酶 1(PLK1)在细胞周期调控中发挥着关键作用,并且与肿瘤的生长和预后相关。在这里,我们旨在测试 PLK1 抑制剂 BI 2536 对 8 种 GBM 细胞系的放射增敏作用。对于细胞周期分析,用 10、50 或 100 nM BI 2536 处理 T98G、U251、U343 MG-a、LN319、SF188、U138 MG 和 U87 MG 细胞系 24 小时。此外,将暴露于 BI 2536 50 nM 24 小时的细胞培养物用 60Co 源的γ射线照射,最终剂量为 2、4 和 6 Gy。通过增殖和集落形成能力测定评估联合效应。BI 2536 处理 24 小时后导致有丝分裂停滞,并增加 GBM 细胞的凋亡。此外,我们的结果表明,这种药物的预处理使七种 GBM 细胞系中的六种对不同剂量的γ辐射敏感,表现为生长减少和集落形成能力丧失。我们的数据表明,PLK1 阻断对 GBM 具有放射增敏作用,这可以改善这种毁灭性肿瘤的治疗策略。

相似文献

1
Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.抑制 Polo 样激酶 1 诱导细胞周期停滞并增强脑胶质瘤细胞对电离辐射的敏感性。
Cancer Biother Radiopharm. 2013 Sep;28(7):516-22. doi: 10.1089/cbr.2012.1415. Epub 2013 May 28.
2
Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.Polo-like kinase 1 抑制可杀死多形性胶质母细胞瘤脑肿瘤细胞,部分原因是 Sox2 的丧失,并可延缓小鼠肿瘤的进展。
Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.
3
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.Polo-like kinase 1 抑制通过细胞周期阻滞导致增殖减少,从而导致胶质母细胞瘤细胞死亡。
Cancer Gene Ther. 2013 Sep;20(9):499-506. doi: 10.1038/cgt.2013.46. Epub 2013 Jul 26.
4
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.多形性胶质母细胞瘤中 polo 样激酶 1 的抑制诱导有丝分裂灾难并增强放射敏感性。
Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.
5
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.PLK1抑制使乳腺癌细胞对放疗敏感,但作为单一疗法或与其他细胞毒性药物联合使用时疗效较低。
Anticancer Agents Med Chem. 2018;18(9):1252-1257. doi: 10.2174/1871520618666180228155435.
6
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.一项高内涵小分子筛选确定了胶质母细胞瘤干细胞对抑制polo样激酶1的敏感性。
PLoS One. 2013 Oct 30;8(10):e77053. doi: 10.1371/journal.pone.0077053. eCollection 2013.
7
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.抑制 Polo 样激酶 1 导致骨肉瘤细胞在体外和体内生长受到抑制。
Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.
8
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.Polo-like kinase 1 (PLK1) 抑制可抑制成神经管细胞瘤细胞的生长并增强其对辐射的敏感性。
BMC Cancer. 2012 Mar 5;12:80. doi: 10.1186/1471-2407-12-80.
9
Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.同时抑制 PLK1 可改善分割放疗后的局部肿瘤控制。
Radiother Oncol. 2013 Sep;108(3):422-8. doi: 10.1016/j.radonc.2013.06.038. Epub 2013 Jul 25.
10
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.艾日布林与Polo样激酶1抑制剂协同作用,诱导横纹肌肉瘤细胞凋亡。
Cancer Lett. 2015 Aug 28;365(1):37-46. doi: 10.1016/j.canlet.2015.04.011. Epub 2015 Apr 23.

引用本文的文献

1
Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat.阿利塞替布和巴瑞替尼通过与BH3模拟物和帕比司他序贯联合,在多发性骨髓瘤中诱导细胞周期停滞和线粒体相关的细胞死亡,并增强疗效。
Cancers (Basel). 2025 Jul 9;17(14):2290. doi: 10.3390/cancers17142290.
2
Bioinformatics analysis to identify key invasion related genes and construct a prognostic model for glioblastoma.生物信息学分析以鉴定关键的侵袭相关基因并构建胶质母细胞瘤的预后模型。
Sci Rep. 2025 Mar 28;15(1):10773. doi: 10.1038/s41598-025-95067-x.
3
Single-cell morphological and transcriptome analysis unveil inhibitors of polyploid giant breast cancer cells in vitro.单细胞形态和转录组分析揭示体外多倍体巨乳腺癌细胞的抑制剂。
Commun Biol. 2023 Dec 21;6(1):1301. doi: 10.1038/s42003-023-05674-5.
4
Public RNA-seq data-based identification and functional analyses reveal that MXRA5 retains proliferative and migratory abilities of dental pulp stem cells.基于公共 RNA-seq 数据的鉴定和功能分析表明,MXRA5 保留了牙髓干细胞的增殖和迁移能力。
Sci Rep. 2023 Sep 20;13(1):15574. doi: 10.1038/s41598-023-42684-z.
5
Uncovering transcriptomic landscape alterations of CAN-2409 in and glioma models.揭示CAN-2409在[具体内容缺失]和胶质瘤模型中的转录组景观改变。
Front Med (Lausanne). 2023 May 9;10:1140352. doi: 10.3389/fmed.2023.1140352. eCollection 2023.
6
Predicting anti-cancer drug combination responses with a temporal cell state network model.基于时变细胞状态网络模型预测抗癌药物组合的反应。
PLoS Comput Biol. 2023 May 1;19(5):e1011082. doi: 10.1371/journal.pcbi.1011082. eCollection 2023 May.
7
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.靶向小儿肿瘤学中被劫持的激酶信号通路:机遇与现状
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.
8
Extracting functional insights from loss-of-function screens using deep link prediction.利用深度链接预测从功能丧失筛选中提取功能见解。
Cell Rep Methods. 2022 Feb 17;2(2):100171. doi: 10.1016/j.crmeth.2022.100171. eCollection 2022 Feb 28.
9
Investigating Molecular Determinants of Cancer Cell Resistance to Ionizing Radiation Through an Integrative Bioinformatics Approach.通过综合生物信息学方法研究癌细胞对电离辐射抗性的分子决定因素。
Front Cell Dev Biol. 2021 Apr 7;9:620248. doi: 10.3389/fcell.2021.620248. eCollection 2021.
10
Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments.儿童高级别胶质瘤中的放射增敏作用:靶点、耐药性与进展
Front Oncol. 2021 Apr 1;11:662209. doi: 10.3389/fonc.2021.662209. eCollection 2021.

本文引用的文献

1
Switching Polo-like kinase-1 on and off in time and space.在时间和空间上适时开关 Polo-like kinase-1。
Trends Biochem Sci. 2012 Dec;37(12):534-42. doi: 10.1016/j.tibs.2012.09.005. Epub 2012 Nov 6.
2
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.验证 Polo-like kinase 1 作为胰腺癌治疗靶点的可行性。
Cancer Biol Ther. 2012 Oct;13(12):1214-20. doi: 10.4161/cbt.21412. Epub 2012 Aug 15.
3
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.Polo-like kinase 1 是肝细胞癌的一个新的治疗靶点。
World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.
4
Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck.Polo样激酶-1抑制剂BI2536对头颈部鳞状细胞癌细胞系的作用
Oncol Lett. 2012 Jul;4(1):175-177. doi: 10.3892/ol.2012.700. Epub 2012 Apr 30.
5
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.一项开放标签、剂量递增的 I 期研究,评估静脉注射 BI 2536 联合培美曲塞在既往治疗的非小细胞肺癌患者中的疗效。
Clin Lung Cancer. 2013 Jan;14(1):19-27. doi: 10.1016/j.cllc.2012.04.003. Epub 2012 Jun 1.
6
The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.药物遗传学对癌症患者放射治疗效果的影响。以 DNA 损伤反应基因为重点。
Cancer Treat Rev. 2012 Oct;38(6):737-59. doi: 10.1016/j.ctrv.2012.02.004. Epub 2012 Mar 2.
7
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.索拉非尼联合电离辐射在乳腺癌模型中具有更强的抗肿瘤活性。
Anticancer Drugs. 2012 Jun;23(5):525-33. doi: 10.1097/CAD.0b013e32834ea5b3.
8
In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines.DTA0100 与辐射在人癌细胞系中的体外协同相互作用。
Anticancer Agents Med Chem. 2012 Oct 1;12(8):988-93. doi: 10.2174/187152012802650057.
9
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.在晚期实体瘤患者中连续静脉输注 Plk1 抑制剂 BI 2536 3 天的 I 期研究。
Curr Oncol. 2012 Feb;19(1):e28-35. doi: 10.3747/co.19.866.
10
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.抑制 Aurora 激酶可增强胶质母细胞瘤细胞对替莫唑胺的化疗敏感性并引起放射增敏作用。
J Cancer Res Clin Oncol. 2012 Mar;138(3):405-14. doi: 10.1007/s00432-011-1111-0. Epub 2011 Dec 9.